CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.1800
-0.0100 (-0.84%)
At close: 4:00PM EDT

1.1600 -0.02 (-1.69%)
After hours: 4:33PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.1900
Open1.1900
Bid1.1600 x 3200
Ask1.1700 x 2200
Day's Range1.1500 - 1.2200
52 Week Range0.6200 - 3.5900
Volume491,008
Avg. Volume3,448,253
Market Cap43.167M
Beta (5Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-0.9540
Earnings DateAug 04, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 12-May-20 8:30pm GMT

    Q1 2020 Curis Inc Earnings Call

  • Curis Announces $17.5 Million Registered Direct Offering
    PR Newswire

    Curis Announces $17.5 Million Registered Direct Offering

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 14,000,000 of its shares of common stock at a purchase price of $1.25 per share in a registered direct offering. The closing of the offering is expected to occur on or about June 15, 2020, subject to the satisfaction of customary closing conditions.

  • Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
    PR Newswire

    Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Curis plans to initiate a Phase 1a/1b study of CI-8993 in the second half of 2020.

  • Do Hedge Funds Love Curis, Inc. (CRIS)?
    Insider Monkey

    Do Hedge Funds Love Curis, Inc. (CRIS)?

    In this article you are going to find out whether hedge funds think Curis, Inc. (NASDAQ:CRIS) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 19-Mar-20 8:30pm GMT

    Q4 2019 Curis Inc Earnings Call

  • Curis Reports First Quarter 2020 Financial Results
    PR Newswire

    Curis Reports First Quarter 2020 Financial Results

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2020.

  • Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020
    PR Newswire

    Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12, 2020, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET.

  • Curis to Present at 19th Annual Needham Virtual Healthcare Conference
    PR Newswire

    Curis to Present at 19th Annual Needham Virtual Healthcare Conference

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. ET.

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2020, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 110,000 shares of Curis common stock to three new employees, with a grant date of April 1, 2020 (the "Q2 2020 Inducement Grants").

  • Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
    PR Newswire

    Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019.

  • ACCESSWIRE

    Curis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Curis, Inc. (NASDAQ:CRIS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at 4:30 PM Eastern ...

  • Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020
    PR Newswire

    Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2019 financial results on Thursday, March 19, 2020, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET.

  • Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
    PR Newswire

    Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital").

  • Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
    PR Newswire

    Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an amendment of its collaboration, license and option agreement with Aurigene Discovery Technologies, Ltd. (Aurigene). Under the terms of the amended agreement, Aurigene will fund and conduct a Phase 2b/3 randomized study evaluating CA-170, an orally available, dual inhibitor of VISTA and PDL1, in combination with chemoradiation, in approximately 240 patients with non-squamous non-small cell lung cancer (nsNSCLC). In turn, Aurigene receives rights to develop and commercialize CA-170 in Asia, in addition to its existing rights in India and Russia, based on the terms of the original agreement. Curis retains U.S., E.U., and rest of world rights to CA-170, and is entitled to receive royalty payments on potential future sales of CA-170 in Asia.

  • Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies
    PR Newswire

    Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

    Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based algorithms, CLIA-approved technologies, and novel, validated approaches focused on Master Regulator (MR) proteins and tumor checkpoints to: (a) better understand and articulate the role of MYC in fimepinostat's mechanism of action; and (b) explore additional potential novel biomarkers that may help patient selection in hematologic and solid tumors clinical studies.

  • Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
    PR Newswire

    Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993 (formerly JNJ-61610588). CI-8993 is a clinical-stage monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA) signaling pathway.

  • Should You Buy Curis, Inc. (CRIS)?
    Insider Monkey

    Should You Buy Curis, Inc. (CRIS)?

    We can judge whether Curis, Inc. (NASDAQ:CRIS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • The Curis (NASDAQ:CRIS) Share Price Is Up 103% And Shareholders Are Boasting About It
    Simply Wall St.

    The Curis (NASDAQ:CRIS) Share Price Is Up 103% And Shareholders Are Boasting About It

    Some Curis, Inc. (NASDAQ:CRIS) shareholders are probably rather concerned to see the share price fall 37% over the...

  • Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
    PR Newswire

    Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing Phase 1 dose escalation study of CA-4948, an IRAK4 kinase inhibitor, for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Curis Inc Earnings Call

  • Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology
    PR Newswire

    Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...

  • Curis Reports Third Quarter 2019 Financial Results
    PR Newswire

    Curis Reports Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2019. "We are pleased by the safety and tolerability profile of CA-170 in our Phase 1 study and continue to believe VISTA is an important and scientifically-validated target. Curis is evaluating fimepinostat (a MYC suppressor) with venetoclax (a BCL-2 inhibitor) combination regimen in an ongoing Phase 1 study in diffuse large B-cell lymphoma (DLBCL), including patients with double-hit/double-expressor (DH/DE) lymphoma.

  • /U P D A T E D -- Curis, Inc./
    PR Newswire

    /U P D A T E D -- Curis, Inc./

    In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq market open, not after market close. LEXINGTON, Mass., Oct. 29, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, before the open of US markets. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

  • Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019
    PR Newswire

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019

    LEXINGTON, Mass., Oct. 29, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire

    Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis, will present at the Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019 at 3:00 p.m. ET in New York, NY. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.